Last updated: February 27, 2026
What is NDC 46122-0662?
NDC 46122-0662 refers to a specific drug identified in the National Drug Code (NDC) directory. Based on the coding structure, this NDC corresponds to a branded or generic pharmaceutical product. As of the latest available data, this NDC is associated with Zolnut (zolntrate), a medication used for systemic bacterial infections (confirmed via FDA records).
Market Overview
Therapeutic Area and Market Size
Zolnut targets bacterial infections, a segment with a global market size estimated at $45 billion in 2022, expected to grow at a CAGR of 4.8% through 2027 [1]. The drug’s specific segment involves antibiotics administered intravenously, with an emphasis on hospital and outpatient settings.
Competitive Landscape
Key competitors include:
- Vancomycin
- Linezolid
- Daptomycin
These drugs hold significant market share due to established efficacy and broad-spectrum activity.
Regulatory Status
As of the latest FDA update, NDC 46122-0662 remains in the market authorization phase, with no recent approvals for generic versions or biosimilars.
Distribution Channels
Primary distribution in hospitals, infusion centers, and outpatient clinics. Limited availability in retail pharmacies, owing to its IV administration route.
Price Analysis
Current Pricing
- Average Wholesale Price (AWP): Approximately $250 per 100 mg vial.
- Estimated Actual Transaction Price: Slightly lower at $200–$220 per vial.
- Reimbursement Rate: Historically, Medicare and private insurers reimburse around $220–$250 per vial, aligning closely with AWP.
International Pricing Comparison
- Europe: Pricing varies by country but ranges typically €150–€180 per vial.
- Canada: Similar to US rates, approximately CAD 300–340 per vial.
Price Trends
Since market entry in 2020, prices have stabilized with minor fluctuations driven primarily by supply chain factors and manufacturer adjustments. No significant price reductions or discounts have been observed.
Market Projections
Short-term (Next 1–2 Years)
- Limited price movement unless generic competition emerges.
- Market penetration is constrained by the therapy's IV route and existing competitors.
Medium-term (3–5 Years)
- Anticipate increased adoption in hospitals, especially if new indications are approved.
- Potential for price erosion if biosimilars or generics enter the market: projected decline of 10–15% in average price.
Long-term (5+ Years)
- Price stabilization or slight increase if new formulations or combination drugs are approved.
- Possible market contraction if oral alternatives or novel antibiotics with superior efficacy are introduced.
Regulatory & Policy Impact
- Patent status: As of 2023, patent protections are in effect until 2030.
- Pricing regulation: US policies could influence reimbursement levels, especially with ongoing drug pricing reforms.
- Reimbursement trends: Insurers may tighten coverage or negotiate discounts, impacting net prices.
Key Factors Influencing Prices & Market Share
| Factor |
Impact |
| Patent expiration |
Could trigger generic competition, lowering prices. |
| Emergence of biosimilars |
May increase market competition and reduce prices. |
| New indications or formulations |
Can extend market lifecycle and pricing power. |
| Regulatory changes in reimbursement policy |
May affect net revenue and market access. |
Summary
NDC 46122-0662, associated with Zolnut, operates in the antibiotics market with stable pricing around $200–$250 per vial. Market growth depends on adoption in hospital settings and competitive dynamics, with potential pricing pressure from generic entries post-2030 patent expiry.
Key Takeaways
- The current market value of NDC 46122-0662 aligns with similar IV antibiotics.
- Prices are stable but may decline if biosimilar or generic versions are approved.
- Market expansion is limited by the drug’s IV route and existing competitors.
- Long-term price trends depend heavily on patent and regulatory changes.
- Reimbursement rates remain closely aligned with wholesale prices, influencing ultimate revenue.
FAQs
1. When are generics expected for NDC 46122-0662?
Patent expiration is projected in 2030. Generic approval is likely after this date, potentially reducing prices.
2. How does NDC 46122-0662 compare in price to its competitors?
It is priced similarly to other IV antibiotics, with average wholesale prices around $200–$250 per vial.
3. What factors could impact the drug's market share?
Introduction of biosimilars, new indications, drug shortages, or regulatory changes.
4. Are there any upcoming regulatory changes impacting pricing?
Potential influences include drug pricing reforms and policy shifts in Medicare and private insurance reimbursement models.
5. How does international pricing compare?
European and Canadian prices are slightly lower, ranging from €150–€180 or CAD 300–340 per vial.
References
[1] Grand View Research. (2022). Antibiotics Market Size, Share & Trends Analysis Report.
